Printer Friendly

MONOCLONAL MARKET TO EXPLODE WITH NEW CANCER, AUTOIMMUNE DRUGS

 MONOCLONAL MARKET TO EXPLODE WITH NEW CANCER, AUTOIMMUNE DRUGS
 MOUNTAIN VIEW, Calif., May 14 /PRNewswire/ -- Sales of monoclonal antibodies, expected to bring major progress in the treatment of cancers and autoimmune diseases, will balloon by more than 10 times from a $329 million market in the United States in 1991 to $3.8 billion by 1998, projects a new study just released by Market Intelligence.
 The market is projected to grow in large spurts throughout the decade as new products are introduced and approved for therapeutic and diagnostic use, passing $1 billion in 1994 and $2 billion in 1996, said the report, Monoclonal Antibody Markets. This rapid growth will follow several years of modest growth up to 1992. Monoclonal antibody revenues have only been growing at a 10 percent annual rate, in the absence of major new commercial product introductions and with the slowing of the dominant pregnancy-related market.
 Currently promising therapeutic products include those to treat colorectal, prostate, lung, breast, ovarian and lymphatic cancers, as well as leukemia and melanoma. Autoimmune treatments under development include those for multiple sclerosis, rheumatoid arthritis, Type I diabetes, gram-negative sepsis, scleroderma, and lupus. Promising diagnostics for several forms of cancers are also under development. All of these emergent therapeutics and diagnostics are currently in the clinical trial stage or awaiting regulatory approval and ready to hit the market in waves over the next several years.
 Treatment for rheumatoid arthritis has the largest revenue potential of the new therapies, followed by sepsis and breast and colorectal cancer products.
 Presuming that these key products prove safe and effective and get government approval by mid-decade, this market should begin to reach maturity in the late 1990s, with growth rates dropping back to the 20 percent range by 1998.
 Company financial resources as well as technology will continue to be crucial. Small companies need access to large-scale financial resources for their heavy product development costs. Recent stock market conditions have been favorable to such companies, allowing them to obtain financing to support their development work into the future.
 The successive introduction of new products that fight cancers and autoimmune diseases will reduce the proportion of the market held by established products, most prominently those related to pregnancy diagnosis and ovulation prediction. These will plummet as a share from over 70 percent of the total U.S. monoclonal antibody market in 1991 to less than 10 percent of a vastly larger market by 1998.
 The over-the-counter market will grow faster than the professional-based market for these products as the speed, low cost, ease, and accuracy of home tests comes to be increasingly seen as making doctor visits unnecessary.
 Other existing monoclonal antibody markets will continue to grow, although not to anything like the same explosive degree.
 Research, the first monoclonal market to develop in the 1980s and with the largest number of products, has allowed scientists to develop new tests and replace previously used polyclonals and accounted for $40 million in 1991 revenues. The $27.5 million veterinary market grew 16 percent in 1991, while the $35 million contract monoclonal market was up 26 percent.
 Market Intelligence is an international high-technology research firm specializing in pharmaceuticals and other healthcare markets. All Market Intelligence reports are based on extensive interviews with marketing and technical experts from selected companies in each market segment. Primary research is validated by thorough analysis of available secondary research. Since 1982, Market Intelligence has emerged as one of the leading publishers of high-technology market research reports.
 Code: 798-52 Price: $1,995
 TOTAL MONCLONAL ANTIBODY MARKET
 Percent of Revenues by Product Type (U.S.)
 1988-1998
 (In Percentage of Revenues)
 Product Type
 Year Ovula- Preg- Veterin- Reagent Con- Sepsis Rheuma-
 tion nancy ary tract toid
 1988 9.6 63.1 7.2 12.9 7.2 -- --
 1989 9.6 62.0 7.6 12.6 8.2 -- --
 1990 9.5 60.8 8.0 12.4 9.2 -- --
 1991 9.5 60.8 8.4 12.4 10.6 -- --
 1992 6.0 36.7 5.5 7.6 7.8 28.3 --
 1993 5.1 30.6 5.0 6.4 7.7 33.8 --
 1994 3.4 20.3 3.5 4.4 6.1 28.8 23.5
 1995 2.8 16.5 3.1 3.6 6.0 25.5 26.8
 1996 2.1 11.7 2.4 2.7 5.2 18.8 24.0
 1997 1.7 9.4 2.0 2.2 5.2 14.7 22.6
 1998 1.5 8.1 1.9 2.0 5.6 12.2 22.2
 -0- 5/14/92
 /CONTACT: Amy Emerson Arnell of Market Intelligence, 415-961-9000, or 415-961-5042 (fax)/ CO: ST: California IN: MTC SU:


MM-RM -- SJ002 -- 0282 05/14/92 13:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 14, 1992
Words:793
Previous Article:HUGHES SUBMITS TECHNOLOGY FOR ACCEPTANCE AS NATIONAL STANDARD
Next Article:THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
Topics:


Related Articles
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
PROTEIN DESIGN LABS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR SMART M195 ANTIBODY TO TREAT MYELOID LEUKEMIA
CELL GENESYS RECEIVES COMMITMENT FOR ADDITIONAL $10 MILLION FOR DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODY TECHNOLOGY
Repligen Announces Agreement with Amersham Pharmacia Biotech Repligen to Supply Recombinant Protein A to APBiotech.
Coulter and Medarex Announce Broad Human Antibody Collaboration Agreement.
TolerRx Initiates Clinical Trial of TRX4 for Psoriasis.
Biothera Files IND on Imprime PGG(TM) for Combined Therapy With Monoclonal Antibodies for Treatment of Cancer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters